Granger Elder

SEC source: 0001225208-19-012164 · doc4.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,623

SEC source: 0001225208-19-008808 · doc4.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,315

SEC source: 0001225208-19-004403 · doc4.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 995

SEC source: 0001567619-18-008718 · doc1.xml · nonDerivative · entry 2

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,788

SEC source: 0001567619-19-002847 · doc1.xml · nonDerivative · entry 2

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

SEC source: 0000950138-18-000675 · edgar.xml · derivative · entry 4

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 8,006 shares

Expires 2027-05-11

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000675 · edgar.xml · derivative · entry 3

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 7,032 shares

Expires 2026-05-04

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000675 · edgar.xml · derivative · entry 2

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 3,222 shares

Expires 2025-05-06

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000675 · edgar.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement.

F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement.

SEC source: 0001567619-18-008718 · doc1.xml · derivative · entry 5

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,844

Underlying: Common Stock, $0.01 Par Value · 3,844 shares

Expires 2026-05-11

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008718 · doc1.xml · derivative · entry 4

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,376

Underlying: Common Stock, $0.01 Par Value · 3,376 shares

Expires 2026-05-04

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008718 · doc1.xml · derivative · entry 3

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,547

Underlying: Common Stock, $0.01 Par Value · 1,547 shares

Expires 2025-05-06

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008718 · doc1.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,587

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-19-002847 · doc1.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 522

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · shares: Prior to the Merger, the reporting person held Express Scripts restricted stock units. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. The Form 4 filed December 26, 2018 inadvertently included the conversion of those restricted stock units into shares of New Cigna Common Stock based on the merger consideration exchange ratio. This amendment is being filed to correct that administrative error.

F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · balance_after: Prior to the Merger, the reporting person held Express Scripts restricted stock units. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. The Form 4 filed December 26, 2018 inadvertently included the conversion of those restricted stock units into shares of New Cigna Common Stock based on the merger consideration exchange ratio. This amendment is being filed to correct that administrative error.

SEC source: 0001628280-18-015362 · wf-form4_154542663400133.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,816

F1 · security: Grant of restricted stock units pursuant to the Company's 2016 Omnibus Equity Incentive Plan. The award vests in full on September 30, 2019.

SEC source: 0001628280-18-014233 · wf-form4_154212919255718.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,316

F1 · shares: Grant of restricted stock pursuant to the Company's 2016 Omnibus Equity Incentive Plan.

SEC source: 0000950138-18-000371 · edgar.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,523

F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on May 1, 2019, May 1, 2020, and May 1, 2021.

SEC source: 0001628280-17-011560 · wf-form4_151069661098265.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,149

F1 · shares: Grant of restricted stock pursuant to the Company's 2016 Omnibus Equity Incentive Plan.

SEC source: 0000950138-17-000425 · edgar.xml · derivative · entry 2

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,006

Underlying: Express Scripts Holding Company Common Stock · 8,006 shares

Expires 2027-05-11

F2 · price: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on May 1, 2018, May 1, 2019, and May 1, 2020.

F2 · derivative.exercise_date: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on May 1, 2018, May 1, 2019, and May 1, 2020.

SEC source: 0000950138-17-000425 · edgar.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,705

F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on May 1, 2018, May 1, 2019, and May 1, 2020.

SEC source: 0000785557-16-000142 · wf-form4_147915913603982.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,149

F1 · shares: Grant of restricted stock pursuant to the Company's 2016 Omnibus Equity Incentive Plan.

SEC source: 0000785557-16-000127 · wf-form4_147552614805251.xml · derivative · entry 4

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires 2016-11-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: Reflects exercise of previously granted stock options to the reporting person pursuant to the Company's 2006 Long Term Incentive Plan, as amended.

SEC source: 0000785557-16-000127 · wf-form4_147552614805251.xml · derivative · entry 3

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,024 shares

Expires 2016-09-21

F2 · security: Subscription Rights (right to buy)

SEC source: 0000785557-16-000127 · wf-form4_147552614805251.xml · nonDerivative · entry 2

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,524

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000785557-16-000127 · wf-form4_147552614805251.xml · nonDerivative · entry 1

Granger Elder · CIK 0001625579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,024

F1 · shares: Represents shares of the issuer's common stock purchased by the reporting person from the exercise of his basic subscription rights in the issuer's rights offering issued pro rata to holders of common stock of DLH Holdings Corp. on the August 19, 2016 record date for the rights offering. The closing of the rights offering occurred on September 29, 2016.